Adaptive Biotechnologies Corp 8-K

What Happened Adaptive Biotechnologies Corporation filed an 8-K on June 15, 2026, announcing it intends to offer $250 million aggregate principal amount of convertible senior notes due 2031, subject to market conditions and other factors. The offering is being made to persons believed to be qualified institutional buyers under Rule 144A. On the same date the company also announced it intends to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company issued press releases and a statement providing additional information; these materials are included as exhibits to the filing.

Key Details

• Offering size: $250.0 million aggregate principal amount of convertible senior notes due 2031.
• Additional option: expected 13-day option for initial purchasers to buy up to an additional $37.5 million (15% of the offering).
• Target investors: limited to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A.
• Corporate action: intends to pursue a separation (business split) of the MRD and Immune Medicine businesses; additional information provided in company statement and press release (filed June 15, 2026).

Why It Matters This is a financing move that could raise cash for the company and support the planned separation of its MRD and Immune Medicine units. Convertible notes can later convert into common stock, which may dilute existing shareholders depending on final terms (conversion rate and other terms were not provided in the filing). The announcement is preliminary and subject to market conditions and final documentation; it is not an offer to sell the notes or any shares. Investors should watch for follow-up filings with final terms, any shareholder votes or transaction details related to the separation, and how the company intends to use the proceeds.